You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • +6 more
  • Beijing, China
    Beijing Cancer Hospital
Feb 6, 2023

Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma (MZL)
  • Chiang Mai, Thailand
    Chiang Mai University
Nov 20, 2023

Diffuse Large B Cell Lymphoma Trial in Rouen (Measure of the circulating tumor DNA)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Measure of the circulating tumor DNA
  • Rouen, France
    Centre Henri Becquerel
Nov 17, 2023

B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)

Recruiting
  • B-Cell Non Hodgkin Lymphoma
  • B-Cell Acute Lymphoblastic Leukemia
  • anti-CD19 CAR T-cells
  • Hanoi, Vietnam
    Vinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023

Non-hodgkin Lymphoma Trial (HY004)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • HY004
  • (no location specified)
Aug 21, 2023

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023

B-cell Non-Hodgkin's Lymphoma Trial (SHR-A1912; R-Chemo)

Not yet recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • SHR-A1912; R-Chemo
  • (no location specified)
Oct 23, 2023

Navigating the Clinical Research Process for Lymphoma

Not yet recruiting
  • Lymphoma
    • San Francisco, California
      Power Life Sciences
    Sep 30, 2023

    Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • Refractory Diffuse Large B-cell Lymphoma
    • RC19D2 cell injection
    • Tianjin, Tianjin, China
      Hematology Hospital of the Chinese Academy of Medical Sciences
    Sep 14, 2023

    T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

    Recruiting
    • T-cell Lymphoma
    • +30 more
    • Optional Blood Sample
    • Optional Nail Sample
    • Duarte, California
    • +25 more
    Jul 28, 2023

    Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

    Not yet recruiting
    • Lymphoma, B-Cell
    • +6 more
    • Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
    • Guayaquil, Guayas, Ecuador
      Instituto Oncológico Nacional Dr. Juan Tanca Marengo
    Apr 27, 2023

    Lymphoma-associated Hemophagocytic Lymphohistiocytosis

    Recruiting
    • Lymphoma
    • Hemophagocytic Lymphohistiocytoses
      • Birmingham, Alabama
        University of Alabama at Birmingham
      Jun 1, 2023

      OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)

      Not yet recruiting
      • OR Regimen Refractory Marginal Zone Lymphoma
      • obrutinib, rituximab
      • (no location specified)
      Nov 12, 2023

      B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

      Recruiting
      • B-cell Acute Lymphoblastic Leukemia
      • +2 more
      • CD19/CD22-bispecific CAR-T cells
      • Beijing, Beijing, China
        Liang Wang
      Oct 7, 2023

      Lymphoma Trial in Haifa (procedure, dietary supplement, behavioral)

      Recruiting
      • Lymphoma
      • Acupuncture
      • +5 more
      • Haifa, Israel
        Bnai Zion Medical Center
      Jul 30, 2023

      DLBCL Trial (Polatuzumab Vedotin)

      Not yet recruiting
      • Diffuse Large B-Cell Lymphoma
      • Polatuzumab Vedotin
      • (no location specified)
      Jul 12, 2023

      Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

      Recruiting
      • Relapsed or Refractory CD19+ B-cell Lymphoma
      • +2 more
      • TBI-2001
      • +2 more
      • Toronto, Ontario, Canada
        Princess Margaret Cancer Centre
      Jul 26, 2023

      T-cell Lymphoma Patients After First-line Treatment Failure Trial (SHR2554; Chidamide analog tablets, SHR2554 analog tablets;

      Not yet recruiting
      • T-cell Lymphoma Patients After First-line Treatment Failure
      • SHR2554; Chidamide analog tablets
      • SHR2554 analog tablets; Chidamide
      • (no location specified)
      Nov 5, 2023

      Hodgkin Lymphoma Trial in Cologne (Pembrolizumab)

      Not yet recruiting
      • Hodgkin Lymphoma
      • Cologne, Germany
        1st Department of Medicine, Cologne University Hospital
      Sep 19, 2023

      Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

      Not yet recruiting
      • Mantle-cell Lymphoma
      • Polatuzumab, bendamustin und rituximab
      • (no location specified)
      May 11, 2023

      T Cell Lymphoma Trial in New Haven (Mogamulizumab, DA-EPOCH Protocol)

      Not yet recruiting
      • T Cell Lymphoma
      • New Haven, Connecticut
        Yale Smilow Cancer Hospital
      Aug 14, 2023

      SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

      Not yet recruiting
      • B-cell Non Hodgkin Lymphoma
      • +2 more
        • (no location specified)
        Jun 22, 2023

        Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

        Recruiting
        • Extranodal NK T Cell Lymphoma
        • NK-Cell Leukemia
        • Anti-CD56 CAR T
        • Xuzhou, Jiangsu, China
          The Affiliated Hospital of Xuzhou Medical University
        Jul 10, 2023

        Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult Trial in Boston (Epcoritamab, Rituximab)

        Not yet recruiting
        • Follicular Lymphoma
        • Low Grade Non-Hodgkin's Lymphoma, Adult
        • Boston, Massachusetts
          Dana-Farber Cancer Institute
        Mar 13, 2023

        CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

        Active, not recruiting
        • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
        • DISEASE
        • (no location specified)
        May 4, 2023